Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in Rats
- 1 December 2000
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 17 (12) , 1494-1502
Abstract
Purpose. Amphotericin B in small, unilamellar liposomes (AmBisome) is safer and produces higher plasma concentrations than other formulations. Because liposomes may increase and prolong tissue...Keywords
This publication has 27 references indexed in Scilit:
- Lipid-based amphotericin B formulations: from animals to manPharmaceutical Science & Technology Today, 1999
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Pharmacokinetics, Distribution in Serum Lipoproteins and Tissues, and Renal Toxicities of Amphotericin B and Amphotericin B Lipid Complex in a Hypercholesterolemic Rabbit Model: Single-Dose StudiesAntimicrobial Agents and Chemotherapy, 1998
- Comparative Intravenous Toxicity of Cisplatin Solution and Cisplatin Encapsulated in Long-Circulating, Pegylated Liposomes in Cynomolgus Monkeys,Toxicological Sciences, 1998
- Liposomal Amphotericin BDrugs, 1998
- A High-Performance Liquid Chromatographic Assay for the Determination of Amphotericin B Serum Concentrations After the Administration of AmBisome, a Liposomal Amphotericin B FormulationTherapeutic Drug Monitoring, 1996
- Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosisJournal of Antimicrobial Chemotherapy, 1993
- Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogsAntimicrobial Agents and Chemotherapy, 1992
- Reversible depression of the reticuloendothelial system by liposomesBiochimica et Biophysica Acta (BBA) - General Subjects, 1982
- Hypocholesterolemic effect of amphotericin B: an analytical approach.1974